Company intelligence / Profile preview

Neogenium

Amsterdam, Netherlands

Ownership: Private
Development stage: Commercial

Overview

Neogene has developed a pipeline of fully individualized and shared neoantigen-targeting TCR therapies for solid tumors. The company’s expertise lies in discovering and manufacturing next-generation T-cell receptor therapies with the aim of transforming treatment options for patients with hard-to-treat cancers

Therapeutic areas: Oncology
Modalities: T cell receptor engineered T cell therapyCell therapy
Industry: Biotech

Partnerships

AstraZeneca is the acquirer and parent company. No other major partnerships disclosed post-acquisition

Beyond the preview

Go deeper on Neogenium.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Neogenium.

Explore the full profile